Epstein-Barr virus: exploiting the immune system
10.1038/35095584
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Immunology (297)
Authors 1
  1. David A. Thorley-Lawson (first)
References 90 Referenced 741
  1. Chen, F. et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69, 3752–3758 (1995). (10.1128/JVI.69.6.3752-3758.1995) / J. Virol. by F Chen (1995)
  2. Tierney, R. J., Steven, N., Young, L. S. & Rickinson, A. B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68, 7374–7385 (1994). (10.1128/JVI.68.11.7374-7385.1994) / J. Virol. by RJ Tierney (1994)
  3. Qu, L. & Rowe, D. T. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66, 3715–3724 (1992). (10.1128/JVI.66.6.3715-3724.1992) / J. Virol. by L Qu (1992)
  4. Babcock, G. J., Decker, L. L., Freeman, R. B. & Thorley-Lawson, D. A. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190, 567–576 (1999). (10.1084/jem.190.4.567) / J. Exp. Med. by GJ Babcock (1999)
  5. Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. EBV persistence involves strict selection of latently infected B cells. J. Immunol. 165, 2975–2981 (2000). (10.4049/jimmunol.165.6.2975) / J. Immunol. by AM Joseph (2000)
  6. Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395–404 (1998). (10.1016/S1074-7613(00)80622-6) / Immunity by GJ Babcock (1998)
  7. Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71, 4882–4891 (1997). (10.1128/JVI.71.7.4882-4891.1997) / J. Virol. by EM Miyashita (1997)
  8. Henle, W. & Henle, G. in The Epstein-Barr Virus (eds Epstein, M. A. & Achong, B. G.) 61–78 (Springer–Verlag, Berlin, 1979). (10.1007/978-3-642-67236-1_4) / The Epstein-Barr Virus by W Henle (1979)
  9. Khan, G., Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5, 173–179 (1996). (10.1016/S1074-7613(00)80493-8) / Immunity by G Khan (1996)
  10. Yao, Q. Y., Rickinson, A. B. & Epstein, M. A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. J. Cancer 35, 35–42 (1985). (10.1002/ijc.2910350107) / Int. J. Cancer by QY Yao (1985)
  11. Tan, L. C. et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827–1835 (1999). (10.4049/jimmunol.162.3.1827) / J. Immunol. by LC Tan (1999)
  12. Coffey, A. J. et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genet. 20, 129–135 (1998). (10.1038/2424) / Nature Genet. by AJ Coffey (1998)
  13. Sayos, J. et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395, 462–469 (1998). (10.1038/26683) / Nature by J Sayos (1998)
  14. Hamilton, J. K. et al. X-linked lymphoproliferative syndrome registry report. J. Pediatr. 96, 669–673 (1980). (10.1016/S0022-3476(80)80735-9) / J. Pediatr. by JK Hamilton (1980)
  15. Purtilo, D. T., Cassel, C. K., Yang, J. P. & Harper, R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1, 935–940 (1975). (10.1016/S0140-6736(75)92004-8) / Lancet by DT Purtilo (1975)
  16. Pope, J. H., Horne, M. K. & Scott, W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer 3, 857–866 (1968). (10.1002/ijc.2910030619) / Int. J. Cancer by JH Pope (1968)
  17. Aman, P., Ehlin-Henriksson, B. & Klein, G. Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J. Exp. Med. 159, 208–220 (1984). (10.1084/jem.159.1.208) / J. Exp. Med. by P Aman (1984)
  18. Thorley-Lawson, D. A. & Mann, K. P. Early events in Epstein-Barr virus infection provide a model for B cell activation. J. Exp. Med. 162, 45–59 (1985). (10.1084/jem.162.1.45) / J. Exp. Med. by DA Thorley-Lawson (1985)
  19. Rickinson, A. B. & Kieff, E. in Virology 3rd edn Vol. 2 (eds Fields, B. N., Knipe, D. M., & Howley, P. M.) 2397–2446 (Lippincott–Raven, Philadelphia, 1996). / Virology by AB Rickinson (1996)
  20. Brooks, L., Yao, Q. Y., Rickinson, A. B. & Young, L. S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66, 2689–2697 (1992). (10.1128/JVI.66.5.2689-2697.1992) / J. Virol. by L Brooks (1992)
  21. Babcock, J. G., Hochberg, D. & Thorley-Lawson, A. D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497–506 (2000). (10.1016/S1074-7613(00)00049-2) / Immunity by JG Babcock (2000)
  22. Babcock, G. J. & Thorley-Lawson, D. A. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl Acad. Sci. USA 97, 12250–12255 (2000). (10.1073/pnas.200366597) / Proc. Natl Acad. Sci. USA by GJ Babcock (2000)
  23. Thorley-Lawson, D. A. & Babcock, G. J. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 65, 1433–1453 (1999). (10.1016/S0024-3205(99)00214-3) / Life Sci. by DA Thorley-Lawson (1999)
  24. Fahraeus, R. et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer 42, 329–338 (1988). (10.1002/ijc.2910420305) / Int. J. Cancer by R Fahraeus (1988)
  25. Yates, J. L., Warren, N. & Sugden, B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812–815 (1985). (10.1038/313812a0) / Nature by JL Yates (1985)
  26. Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405–411 (1998). (10.1016/S1074-7613(00)80623-8) / Immunity by RG Caldwell (1998)
  27. Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16, 6131–6140 (1997). (10.1093/emboj/16.20.6131) / EMBO J. by O Gires (1997)
  28. MacLennan, I. C. Germinal centers. Annu. Rev. Immunol. 12, 117–139 (1994). (10.1146/annurev.iy.12.040194.001001) / Annu. Rev. Immunol. by IC MacLennan (1994)
  29. Liu, Y. J. et al. Mechanism of antigen-driven selection in germinal centres. Nature 342, 929–931 (1989). (10.1038/342929a0) / Nature by YJ Liu (1989)
  30. Liu, Y. J. & Arpin, C. Germinal center development. Immunol. Rev. 156, 111–126 (1997). (10.1111/j.1600-065X.1997.tb00963.x) / Immunol. Rev. by YJ Liu (1997)
  31. Mosialos, G. et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389–399 (1995). (10.1016/0092-8674(95)90489-1) / Cell by G Mosialos (1995)
  32. Inoue, J. et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp. Cell Res. 254, 14–24 (2000). (10.1006/excr.1999.4733) / Exp. Cell Res. by J Inoue (2000)
  33. Baker, S. J. & Reddy, E. P. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 12, 1–9 (1996). / Oncogene by SJ Baker (1996)
  34. Banchereau, J. et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881–922 (1994). (10.1146/annurev.iy.12.040194.004313) / Annu. Rev. Immunol. by J Banchereau (1994)
  35. Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17, 1700–1709 (1998). (10.1093/emboj/17.6.1700) / EMBO J. by E Kilger (1998)
  36. Zimber-Strobl, U. et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 15, 7070–7078 (1996). (10.1002/j.1460-2075.1996.tb01098.x) / EMBO J. by U Zimber-Strobl (1996)
  37. Beaufils, P., Choquet, D., Mamoun, R. Z. & Malissen, B. The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J. 12, 5105–5112 (1993). (10.1002/j.1460-2075.1993.tb06205.x) / EMBO J. by P Beaufils (1993)
  38. Miller, C. L. et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2, 155–166 (1995). (10.1016/S1074-7613(95)80040-9) / Immunity by CL Miller (1995)
  39. Kurosaki, T. Genetic analysis of B cell antigen receptor signaling. Annu. Rev. Immunol. 17, 555–592 (1999). (10.1146/annurev.immunol.17.1.555) / Annu. Rev. Immunol. by T Kurosaki (1999)
  40. Maruyama, M., Lam, K. P. & Rajewsky, K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407, 636–642 (2000). (10.1038/35036600) / Nature by M Maruyama (2000)
  41. Lam, K. P., Kuhn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073–1083 (1997). (10.1016/S0092-8674(00)80373-6) / Cell by KP Lam (1997)
  42. Hoagland, R. J. The transmission of infectious mononucleosis. Am. J. Med. Sci. 229, 262–272 (1955). (10.1097/00000441-195503000-00003) / Am. J. Med. Sci. by RJ Hoagland (1955)
  43. Gordadze, A. V. et al. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J. Virol. 75, 5899–5912 (2001). (10.1128/JVI.75.13.5899-5912.2001) / J. Virol. by AV Gordadze (2001)
  44. Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol. 74, 9964–9971 (2000). (10.1128/JVI.74.21.9964-9971.2000) / J. Virol. by AM Joseph (2000)
  45. Ling, P. D., Hsieh, J. J., Ruf, I. K., Rawlins, D. R. & Hayward, S. D. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. J. Virol. 68, 5375–5383 (1994). (10.1128/JVI.68.9.5375-5383.1994) / J. Virol. by PD Ling (1994)
  46. Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309–314 (2000). (10.1038/35018581) / Nature by KM Ansel (2000)
  47. Polack, A. et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)- transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl Acad. Sci. USA 93, 10411–10416 (1996). (10.1073/pnas.93.19.10411) / Proc. Natl Acad. Sci. USA by A Polack (1996)
  48. Hofelmayr, H., Strobl, L. J., Marschall, G., Bornkamm, G. W. & Zimber-Strobl, U. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J. Virol. 75, 2033–2040 (2001). (10.1128/JVI.75.5.2033-2040.2001) / J. Virol. by H Hofelmayr (2001)
  49. Uchida, J. et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286, 300–303 (1999). (10.1126/science.286.5438.300) / Science by J Uchida (1999)
  50. Araujo, I. et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J. Pathol. 187, 326–330(1999). (10.1002/(SICI)1096-9896(199902)187:3<326::AID-PATH242>3.0.CO;2-N) / J. Pathol. by I Araujo (1999)
  51. Anagnostopoulos, I., Hummel, M., Kreschel, C. & Stein, H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 85, 744–750 (1995). (10.1182/blood.V85.3.744.bloodjournal853744) / Blood by I Anagnostopoulos (1995)
  52. Kurth, J. et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13, 485–495 (2000). (10.1016/S1074-7613(00)00048-0) / Immunity by J Kurth (2000)
  53. Selin, L. K., Varga, S. M., Wong, I. C. & Welsh, R. M. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188, 1705–1715 (1998). (10.1084/jem.188.9.1705) / J. Exp. Med. by LK Selin (1998)
  54. Khanna, R., Moss, D. J. & Burrows, S. R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170, 49–64 (1999). (10.1111/j.1600-065X.1999.tb01328.x) / Immunol. Rev. by R Khanna (1999)
  55. Carbone, A., Tirelli, U., Gloghini, A., Volpe, R. & Boiocchi, M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol. 11, 1674–1681 (1993). (10.1200/JCO.1993.11.9.1674) / J. Clin. Oncol. by A Carbone (1993)
  56. Thomas, J. A. et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49, 944–953 (1990). (10.1097/00007890-199005000-00022) / Transplantation by JA Thomas (1990)
  57. Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9–13 (1995). (10.1016/S0140-6736(95)91150-2) / Lancet by CM Rooney (1995)
  58. Wang, D., Liebowitz, D. & Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831–840 (1985). (10.1016/0092-8674(85)90256-9) / Cell by D Wang (1985)
  59. Staudt, L. M. The molecular and cellular origins of Hodgkin's disease. J. Exp. Med. 191, 207–212 (2000). (10.1084/jem.191.2.207) / J. Exp. Med. by LM Staudt (2000)
  60. Oudejans, J. J. et al. Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J. Clin. Pathol. 49, 897–902 (1996). (10.1136/jcp.49.11.897) / J. Clin. Pathol. by JJ Oudejans (1996)
  61. Pallesen, G., Hamilton-Dutoit, S. J., Rowe, M. & Young, L. S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337, 320–322 (1991). (10.1016/0140-6736(91)90943-J) / Lancet by G Pallesen (1991)
  62. Herbst, H. et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed–Sternberg cells. Proc. Natl Acad. Sci. USA 88, 4766–4770 (1991). (10.1073/pnas.88.11.4766) / Proc. Natl Acad. Sci. USA by H Herbst (1991)
  63. Niedobitek, G. et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90, 1664–1672 (1997). (10.1182/blood.V90.4.1664) / Blood by G Niedobitek (1997)
  64. Hammarskjold, M. L. & Simurda, M. C. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66, 6496–6501 (1992). (10.1128/JVI.66.11.6496-6501.1992) / J. Virol. by ML Hammarskjold (1992)
  65. Brandtzaeg, P., Farstad I. N. & Haraldsen, G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today. 20, 267–277 (1999). (10.1016/S0167-5699(99)01468-1) / Immunol. Today. by P Brandtzaeg (1999)
  66. Klein, U., Rajewsky, K. & Kuppers, R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188, 1679–1689 (1998). (10.1084/jem.188.9.1679) / J. Exp. Med. by U Klein (1998)
  67. Artavanis-Tsakonas, S., Matsuno, K. & Fortini, M. E. Notch signaling. Science 268, 225–232 (1995). (10.1126/science.7716513) / Science by S Artavanis-Tsakonas (1995)
  68. Sullivan, J. L. & Woda, B. A. X-linked lymphoproliferative syndrome. Immunodefic. Rev. 1, 325–347 (1989). / Immunodefic. Rev. by JL Sullivan (1989)
  69. Callan, M. F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395–1402 (1998). (10.1084/jem.187.9.1395) / J. Exp. Med. by MF Callan (1998)
  70. Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1, 702–703 (1964). (10.1016/S0140-6736(64)91524-7) / Lancet by MA Epstein (1964)
  71. Leder, P. in Burkitt's Lymphoma: A Human Cancer Model (eds Lenoir, G. M., O'Conor, G. T. & Olweny, C. L. M.) 341–371 (Oxford Univ. Press, New York, 1985). / Burkitt's Lymphoma: A Human Cancer Model by P Leder (1985)
  72. Manolov, G. & Manolova, Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 237, 33–34 (1972). (10.1038/237033a0) / Nature by G Manolov (1972)
  73. Gregory, C. D., Rowe, M. & Rickinson, A. B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71, 1481–1495 (1990). (10.1099/0022-1317-71-7-1481) / J. Gen. Virol. by CD Gregory (1990)
  74. Muir, C. S. Cancer of the head and neck. Nasopharyngeal cancer. Epidemiology and etiology. J. Am. Med. Assoc. 220, 393–394 (1972). (10.1001/jama.1972.03200030051012) / J. Am. Med. Assoc. by CS Muir (1972)
  75. Andersson-Anvret, M., Forsby, N., Klein, G. & Henle, W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int. J. Cancer 20, 486–494 (1977). (10.1002/ijc.2910200403) / Int. J. Cancer by M Andersson-Anvret (1977)
  76. Yu, M. C., Huang, T. B. & Henderson, B. E. Diet and nasopharyngeal carcinoma: a case-control study in Guangzhou, China. Int. J. Cancer 43, 1077–1082 (1989). (10.1002/ijc.2910430621) / Int. J. Cancer by MC Yu (1989)
  77. Klein, G. in The Epstein-Barr virus (eds Epstein, M. A. & Achong, B. G.) 340–350 (Springer–Verlag, Berlin, 1979). / The Epstein-Barr virus by G Klein (1979)
  78. Niedobitek, G. The Epstein-Barr virus: a group 1 carcinogen? Virchows Arch. 435, 79–86 (1999). (10.1007/s004280050402) / Virchows Arch. by G Niedobitek (1999)
  79. Thorley-Lawson, D. A. in Samter's Immunologic Diseases 6th edn (eds Austen, K. F., Frank, M. M., Atkinson, J. P. & Cantor, H.) 970–985 (Williams and Wilkins, New York, 2001). / Samter's Immunologic Diseases by DA Thorley-Lawson (2001)
  80. Kaiser, C. et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73, 4481–4484 (1999). (10.1128/JVI.73.5.4481-4484.1999) / J. Virol. by C Kaiser (1999)
  81. Parker, G. A. et al. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13, 2541–2549 (1996). / Oncogene by GA Parker (1996)
  82. Hsing, Y., Hostager, B. S. & Bishop, G. A. Characterization of CD40 signaling determinants regulating nuclear factor-κB activation in B lymphocytes. J. Immunol. 159, 4898–4906 (1997). (10.4049/jimmunol.159.10.4898) / J. Immunol. by Y Hsing (1997)
  83. Hanissian, S. H. & Geha, R. S. JAK3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 6, 379–387 (1997). (10.1016/S1074-7613(00)80281-2) / Immunity by SH Hanissian (1997)
  84. Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18, 3064–3073 (1999). (10.1093/emboj/18.11.3064) / EMBO J. by O Gires (1999)
  85. Kieser, A. et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16, 6478–6485 (1997). (10.1093/emboj/16.21.6478) / EMBO J. by A Kieser (1997)
  86. Ishida, T. et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271, 28745–28748 (1996). (10.1074/jbc.271.46.28745) / J. Biol. Chem. by T Ishida (1996)
  87. Brodeur, S. R., Cheng, G., Baltimore, D. & Thorley-Lawson, D. A. Localization of the major NF-κB activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signalling motifs. J. Biol. Chem. 272, 19777–19784 (1997). (10.1074/jbc.272.32.19777) / J. Biol. Chem. by SR Brodeur (1997)
  88. Izumi, K. M. & Kieff, E. D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF- kappaB. Proc. Natl Acad. Sci. USA 94, 12592–12597 (1997). (10.1073/pnas.94.23.12592) / Proc. Natl Acad. Sci. USA by KM Izumi (1997)
  89. Kieser, A., Kaiser, C. & Hammerschmidt, W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J. 18, 2511–2521 (1999). (10.1093/emboj/18.9.2511) / EMBO J. by A Kieser (1999)
  90. Swart, R., Ruf, I. K., Sample, J. & Longnecker, R. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J. Virol. 74, 10838–10845 (2000). (10.1128/JVI.74.22.10838-10845.2000) / J. Virol. by R Swart (2000)
Dates
Type When
Created 22 years, 11 months ago (Sept. 20, 2002, 4:06 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 11:33 p.m.)
Indexed 4 days, 7 hours ago (Aug. 28, 2025, 8:06 a.m.)
Issued 23 years, 11 months ago (Oct. 1, 2001)
Published 23 years, 11 months ago (Oct. 1, 2001)
Published Print 23 years, 11 months ago (Oct. 1, 2001)
Funders 0

None

@article{Thorley_Lawson_2001, title={Epstein-Barr virus: exploiting the immune system}, volume={1}, ISSN={1474-1741}, url={http://dx.doi.org/10.1038/35095584}, DOI={10.1038/35095584}, number={1}, journal={Nature Reviews Immunology}, publisher={Springer Science and Business Media LLC}, author={Thorley-Lawson, David A.}, year={2001}, month=oct, pages={75–82} }